Independent COVID-19 Guides, Resources and Protocols - Reducing Risk of COVID-19 Infection and Severity
Unexpected Comeback of Hydroxychloroquine 2022
Get link
Facebook
Twitter
Pinterest
Email
Other Apps
By
Dr Frank Yap, M.D.
-
If you have followed the development of early treatment protocols for COVID-19, you will be aware that for well over a year, Ivermectin was the central agent in the FLCCC protocol, for prevention and early treatment. Ivermectin is also part of the hospital level protocols.
Very early on, as discussed in this interview with Professor Varon, Hydroxychloroquine was present in the protocol, but it was dropped mid-2020.
This non-inclusion of Hydroxychloroquine appears to have been in part due to the bad publicity that hydroxychloroquine was suffering from, as it was targeted by the mainstream media, especially in relation to the presidential campaign in the US in 2020.
Comeback of Hydroxychloroquine
This January 19, 2022; it’s therefore a bit of a surprise to see Hydroxychloroquine to re-appear in the FLCCC prevention and early treatment protocol.
The move follows the experience of several frontline doctors who found that Hydroxychloroquine is particularly useful to deal with Omicron, in combination with Ivermectin and other agents, as indicated in the protocol.
Hydroxychloroquine and Clinical Evidence (Updated)
As of February 2022 there have been more than 30 studies of Hydroxychloroquine for early treatment with an overall average improvement of 64% as compared to the control groups.
Hydroxychloroquine (HCQ) is not effective when used very late with high dosages over a long period (RECOVERY/SOLIDARITY), effectiveness improves with earlier usage and improved dosing. Early treatment consistently shows positive effects. Negative evaluations typically ignore treatment time, often focusing on a subset of late stage studies.
Here’s a chart from c19early.comthat shows that hydroxychloroquine performs better than ivermectin when given as early treatment in terms of risk reduction of dying from COVID-19:
The overall improvement for hydroxychloroquine is better than ivermectin (for early treatment); 74 % vs 44 % in terms of death rate. Importantly, hydroxychloroquine needs to be given 'early'.
The difference in terms of effectiveness for hydroxychloroquine is distinctly different when given early vs late treatment (64% vs 20%), as shown in the summary chart below:
The evidence tracking on Hydroxychloroquine versus COVID-19 is available at c19hcq.com (constantly updated).
Dr. Peter McCullough is an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas, USA. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough et al. Reviews in Cardiovascular Medicine, 2020 McCullough Protocol 2022 Note and Update: Omicron variant XBB found to be resistant to monoclonal antibody treatments ( New England Journal of Medicine . Dec 2022) Everyone is familiar with nasal and oral swab testing for COVID-19. It should be obvious
Long after the mask mandates, the shut downs and vaccine requirements are little more than a distant memory, the legacy of COVID-19 and the COVID-19 vaccines will continue to haunt us in the form of spike protein. Loss of taste, sleeplessness, low energy – Millions of Americans are needlessly suffering from the long-term effects of COVID19. What’s worse, these symptoms may be magnified if you were vaccinated. Dr. McCullough was one of the most outspoken and bravest leaders during the pandemic, and today he is continuing his work to keep Americans healthy and safe in this new post-pandemic era of spike protein. https://covid19.onedaymd.com/2023/03/dr-peter-mccullough-prescription-and.html Dr. McCullough writes that, Over three years into the pandemic with nearly the entire country having become sick with SARS-CoV-2, a virus engineered to invade the body, there are millions suffering with long-hauler syndrome. Approximately half of patients admitted to the ICU with COVID-19 will have pos
Well-respected North Texas cardiologist, Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. McCullough et al. Reviews in Cardiovascular Medicine, 2020 McCullough Protocol 2022 Note and Update: Omicron variant XBB found to be resistant to monoclonal antibody treatments ( New England Journal of Medicine . Dec 2022) As published in Dr Peter McCullough's substack (Oct
SELF-HELP without a Doctor ( source ) Zinc 50 mg daily (can take half twice daily if upset stomach) Quercetin 500 mg twice a day three times a day if sick (switch to HCQ/IVM if available) Vitamin D3 40,000-50,000 for five days Melatonin 5 mg - 20 mg nightly for 14 days stomach) Pepcid 40-80 daily 14 days – women or Cimetidine 400 daily -men Full Aspirin (325 mg) daily one month N acetyl cysteine (NAC) Up to 2000-2400 mg 1-2 days, then 1000-1200 mg for a week Treatment: Latest Prescriptions ( source ) Monoclonal Antibodies: outpatient, FDA approved, early treatment, within 10 days Only. Note and Update: Omicron variant XBB found to be resistant to monoclonal antibody treatments ( New England Journal of Medicine . Dec 2022) HCQ 200 mg twice a day 7 days or IVM (weight based 0.4/kg) 20-36 mg daily 2-5 days Fenofibrate (Tricor – anti-lipid) 145 mg daily (inflammatory/cytokine phase. Antioxidant) Cyproheptadine (Periactin – antihistamine) 4 mg BID for 14 days (cytokine phase) D
Is povidone iodine the next ivermectin or hydroxychloroquine? Is there any evidence that povidone iodine can treat COVID-19? Iodine 1% Nasal Spray is part of the FLCCC I-CARE early treatment protocol : Nasal spray with 1% povidone-iodine: 2-3 times a day. Do not use for more than 5 days in pregnancy. If 1% product is not available, dilute the more widely available 10% solution and apply 4-5 drops to each nostril every 4 hours. Use 1 % povidone iodine commercial product as per instructions 2–3 x daily. If 1 %-product not available, must first dilute the more widely available 10 %-solution. To make 1% povidone iodine concentrated solution from 10% povidone iodine solution, one dilution method is as follows: – First pour 1½ tablespoons (25ml) of 10% povidone/ iodine solution into a nasal irrigation bottle of 250ml. – Then fill to top with distilled, sterile or previously boiled water. – Tilt head back, apply 4–5 drops to each nostril. Keep tilted for a few minutes, let drain. - Not recom
Treatment should start based on clinical suspicion as soon as possible, preferably within the first 3 days of symptoms. Perform PCR testing, but do not withhold treatment pending results. 'Early' treatment will make significant difference in outcome as opposed to late treatment. To assist all who are having difficulty finding pharmacists to fill prescriptions for ivermectin or hydroxychloroquine (Plaquenil) for preventing or treating COVID-19 , check out Find a Pharmacy to fill Ivermectin (US). See the directory of professionals in US below. Directory of Doctors (by State) Prescribing Effective Outpatient COVID-19 Therapy USA MULTIPLE STATES (Telemedicine or online consultation) The Wellness Company ( twc.health ) Medical Specialty: Family Medicine, Functional Medicine Supported Protocols: I-PREVENT (COVID Protection), I-CARE (Early at-home treatment), I-RECOVER (Long COVID Treatment), I-RECOVER (Po
Dr. Paul Marik and Dr. Pierre Kory are pleased to introduce the I-RECOVER: Post-Vaccine Treatment protocol, designed to help people who have experienced adverse symptoms after a COVID vaccine. Kory and Marik are both part of the FLCCC, which was founded in 2020 to share early treatment protocols for COVID-19. Kory is an ICU specialist, triple board certified in internal medicine, critical care and pulmonary medicine. He now runs a private tele-health practice specializing in the treatment of COVID-19, so-called "long-COVID" and post-vaccine syndrome. Although no official definition exists for post-COVID-vaccine syndrome, a temporal correlation between a patient receiving a COVID-19 vaccine and beginning or worsening of clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes. Note that there are signif
Early treatment is critical and the most important factor in managing this disease. COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is not required. Treatment should be initiated immediately after the onset of flu-like symptoms. The multiple therapies and drugs in this protocol have different mechanisms of action and work synergistically during various phases of the disease. Update: XBB.1.16 ‘Arcturus’ Is New Covid-19 Variant Under Monitoring By The WHO About I-CARE Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Please be sure you are using the latest version of this protocol. Update: T
Zero healthy individuals under the age of 50 have died of COVID-19 in Israel, according to newly released data. “Zero deceased of 18–49 years of age with no underlying morbidities,” the Israel Ministry of Health (MOH) said in response to a formal request from an attorney. Officials noted that the statement only applies to COVID-19 deaths where the MOH conducted an epidemiological investigation and had received information about the underlying diseases. “Zero is a very, very clear number, and cannot be subject to interpretation,” Yoav Yehezkelli , a specialist in internal medicine and medical management, and former lecturer in the Department of Emergency and Disaster Management at Tel Aviv University in Israel, told The Epoch Times. “Why were all the extreme measures of school closures, vaccination of children, and lockdowns needed?” he added. The MOH did respond to a request for comment. Freedom of Information Request The information was sparked by a freedom of information request fi
People who received a COVID-19 vaccine have an increased risk of a serious eye problem, according to a new study. The risk of retinal vascular occlusion “increased significantly” after a first or second dose of the messenger RNA (mRNA) COVID-19 vaccines, researchers reported in a study published by Nature . The Pfizer and Moderna COVID-19 vaccines both use mRNA technology. Retinal vascular occlusion refers to the blockage of veins or vessels that carry blood to or from the retina. It can cause sudden vision loss. Out of 207,626 Pfizer vaccine doses administered in the population that was studied, 226 cases of the eye problem were detected after two years. Among 97,918 Moderna vaccine doses administered, 220 cases were detected over the same time. While some cases were detected among AstraZeneca recipients, the risk wasn’t statistically significant. The risk of retinal vascular occlusion was 3.5 times for vaccinated people compared to an unvaccinated group after 12 weeks and 2.19 times
.png)
Comments
Post a Comment